Latest revenue
$22.0K
as of 2026-03-31
Latest net income
$-3.0M
as of 2026-03-31
Net margin
-13740.9%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think AIM is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.3M
- Enterprise value
- $-39.8K
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.63×
- Dividend yield
- 0.0%
- 52-wk high
- $20.35
- 52-wk low
- $0.21
- Beta
- —
- Shares out
- 14.6M
5-year trend
What this company does
ITEM 1.Business GENERAL AIM ImmunoTech Inc. and its subsidiaries are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders for which there are inadequate or unmet therapies. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. AIM’s products are Ampligen (rintatolimod)…
AI summary unavailable — showing raw filing excerpt
Generated from AIM's filing dated 2026-03-27
Key risks
ITEM 1A.Risk Factors The following cautionary statements identify important factors that could cause our actual results to differ materially from those projected in the forward-looking statements made in this Form 10-K. Please see “Special Note Regarding Forward Looking Statements and Summary Risk Factors” above. Risks Related to Ownership of Our Securities We have a history of losses, expect to continue to incur losses in the near term and may not achieve or sustain profitability in the future, and as a result, there is a substantial doubt about our ability to continue as a going concern. The attached financial statements have been prepared assuming we will continue as a going concern. Our…
AI summary unavailable — showing raw filing excerpt
Generated from AIM's filing dated 2026-03-27
Profitability
Operating margin
-13254.5%
14.0%Net margin
-15861.4%
55.7%Return on equity
142.7%
184.3%Return on assets
-241.4%
20.0%Leverage
Debt / equity
-1.59×
901.4%Long-term debt / equity
-0.09×
Debt / assets
269.2%
1525.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $22.0K | +37.5% | $-3.0M | +18.4% | -13740.9% |
Q4 2025 2025-12-31 | $21.0K | -53.3% | $-4.2M | +30.0% | -19881.0% |
Q3 2025 2025-09-30 | $26.0K | -25.7% | $-3.3M | +11.2% | -12630.8% |
Q2 2025 2025-06-30 | $25.0K | -50.0% | $-2.8M | -52.2% | -11176.0% |
Q1 2025 2025-03-31 | $16.0K | -60.0% | $-3.7M | +36.3% | -23156.3% |
Q4 2024 2024-12-31 | $45.0K | — | $-6.0M | — | -13260.0% |
Q3 2024 2024-09-30 | $35.0K | -23.9% | $-3.7M | +52.7% | -10571.4% |
Q2 2024 2024-06-30 | $50.0K | +19.0% | $-1.8M | +62.6% | -3672.0% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on AIM — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$1.7K
Insider selling
$0
Net activity
+$1.7K
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2025-06-13 | Thomas K Equels CEO & President | Purchase | 107 | $7.70 | $824 | |
| 2025-06-12 | Thomas K Equels CEO & President | Purchase | 103 | $8.70 | $896 |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AIM
Institutional value
$22.1K
Total shares held
37.7K
Distinct holders
8
-4 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | JANE STREET GROUP, LLC | 20.0K | $11.7K | — | New |
| 2 | VANGUARD FIDUCIARY TRUST CO | 17.5K | $10.2K | — | New |
| 3 | Community Bank, N.A. | 132 | $76 | +0 (+0.0%) | No change |
| 4 | CREATIVE FINANCIAL DESIGNS INC /ADV | 30 | $18 | — | New |
| 5 | HOEY INVESTMENTS, INC | 10 | $6 | +0 (+0.0%) | No change |
| 6 | Steward Partners Investment Advisory, LLC | 2 | $1 | +0 (+0.0%) | No change |
| 7 | UBS Group AG | 1 | $1 | -378 (-99.7%) | Trimmed |
| 8 | Farther Finance Advisors, LLC | 1 | $1 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AIM's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.